



C HINESE- A MERICAN L UNG A SSOCIATION



# Transform Scientific Discoveries from a Lab to a Startup 101

January 22<sup>nd</sup>, 2021 Time: **EST 4-5pm; PST: 1-2pm**

(zoom ID: 988 2664 9654; Pass code: CALA2021)



## Dr. George Dai, M.B.A., Ph.D. Co-Chief Investment Officer, Weatherbie Capital, LLC



George Dai is Senior Managing Director and Co-Chief Investment Officer of Weatherbie Capital, LLC. George is the lead Portfolio Manager of Alger Weatherbie Specialized Growth Strategy and Weatherbie Long/Short Strategy. Under his leadership, The Alger Weatherbie Specialized Growth Strategy has achieved top performances in recent years, including being ranked #1 in the Mid-Cap Growth Category during the first quarter of 2019. George has been featured and quoted in a number of publications in leading journals such as New York Times, Investor's Business Daily and Barron's. He was also interviewed on Reuters Television. George received his MBA from the Wharton School, University of Pennsylvania (Director's List), and his Ph.D. in chemistry from Johns Hopkins University. Previously, he earned a B.S. from the University of Science and Technology of China and was a pharmaceutical research scientist at Procter & Gamble. George is a prized Bridge player, and he holds four U.S. patents.

## Peng Lin, Ph.D. J.D, Patent Attorney, Associate, Fish & Richardson



Peng Lin is a patent attorney at Fish & Richardson. He focused on his practice on worldwide patent procurement, patent portfolio management, and strategic planning for life sciences companies. He is currently helping several big Chinese pharmaceutical and biotech companies to develop their IP strategies. Peng received his J.D. cum laude from Harvard Law School, and his Ph.D. in Human and Statistical Genetics from Washington University in St. Louis. He was also named as a Kauffman Fellow for Bio-entrepreneurship at Washington University. Prior to graduate school, Peng earned his B.S. in Biological Science with high honors from Tsinghua University. In addition, Peng has also been actively involved in the management team of the Chinese Antibody Society since 2016. He is currently the vice president of Chinese Antibody Society.

**Topics to cover:** how to translate scientific findings to biomedical products; Keys to protect scientific discoveries by IP; Tips to attract private and public investment et al.

2021 CALA workshop Series  
Moderated by Xiaobo Zhou, Ph.D.